Becton, Dickinson and Company (NYSE:BDX) Shares Sold by Beese Fulmer Investment Management Inc.

Beese Fulmer Investment Management Inc. decreased its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 2.2% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 7,620 shares of the medical instruments supplier’s stock after selling 175 shares during the quarter. Beese Fulmer Investment Management Inc.’s holdings in Becton, Dickinson and Company were worth $1,729,000 at the end of the most recent reporting period.

A number of other institutional investors also recently made changes to their positions in BDX. Livelsberger Financial Advisory purchased a new position in Becton, Dickinson and Company in the 3rd quarter valued at about $26,000. Ashton Thomas Securities LLC purchased a new stake in Becton, Dickinson and Company in the 3rd quarter worth approximately $33,000. Tompkins Financial Corp lifted its stake in shares of Becton, Dickinson and Company by 44.2% during the 3rd quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier’s stock worth $36,000 after purchasing an additional 46 shares during the period. Sound Income Strategies LLC grew its position in shares of Becton, Dickinson and Company by 35.8% in the third quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock valued at $40,000 after purchasing an additional 44 shares during the period. Finally, Kennebec Savings Bank purchased a new position in Becton, Dickinson and Company during the third quarter worth about $46,000. 86.97% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Becton, Dickinson and Company

In other news, EVP David Shan sold 500 shares of the company’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $240.00, for a total transaction of $120,000.00. Following the completion of the transaction, the executive vice president now owns 5,741 shares in the company, valued at approximately $1,377,840. This represents a 8.01 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Shana Carol Neal sold 788 shares of the company’s stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $235.00, for a total transaction of $185,180.00. Following the completion of the transaction, the executive vice president now owns 16,201 shares of the company’s stock, valued at approximately $3,807,235. This trade represents a 4.64 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 9,844 shares of company stock worth $2,210,716. 0.36% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the stock. StockNews.com lowered shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a report on Wednesday, December 18th. Piper Sandler raised their price objective on Becton, Dickinson and Company from $275.00 to $280.00 and gave the stock an “overweight” rating in a report on Tuesday, January 28th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat.com, Becton, Dickinson and Company has an average rating of “Moderate Buy” and a consensus target price of $283.00.

Becton, Dickinson and Company Stock Down 7.1 %

Shares of NYSE:BDX opened at $227.62 on Friday. The firm has a market cap of $66.01 billion, a PE ratio of 38.32, a price-to-earnings-growth ratio of 1.80 and a beta of 0.40. The company has a fifty day simple moving average of $231.79 and a 200 day simple moving average of $234.09. The company has a current ratio of 1.17, a quick ratio of 0.74 and a debt-to-equity ratio of 0.69. Becton, Dickinson and Company has a 12-month low of $218.75 and a 12-month high of $251.99.

Becton, Dickinson and Company (NYSE:BDX) last released its earnings results on Wednesday, February 5th. The medical instruments supplier reported $3.43 EPS for the quarter, topping analysts’ consensus estimates of $3.00 by $0.43. Becton, Dickinson and Company had a return on equity of 14.89% and a net margin of 8.55%. On average, equities research analysts anticipate that Becton, Dickinson and Company will post 14.41 EPS for the current fiscal year.

Becton, Dickinson and Company declared that its board has approved a stock buyback plan on Tuesday, January 28th that authorizes the company to buyback 10,000,000 outstanding shares. This buyback authorization authorizes the medical instruments supplier to reacquire shares of its stock through open market purchases. Shares buyback plans are generally an indication that the company’s management believes its shares are undervalued.

Becton, Dickinson and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, March 31st. Shareholders of record on Monday, March 10th will be issued a dividend of $1.04 per share. The ex-dividend date of this dividend is Monday, March 10th. This represents a $4.16 dividend on an annualized basis and a dividend yield of 1.83%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 70.03%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.